Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The company plans to offer 2.73 million shares priced between $10 and $12 each.
The portfolio consists of acute, chronic and oncology products.
A look at why these two biopharma companies could have targets on their backs.
Fosun Pharma acquired China rights to market a novel treatment for Parkinson’s disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.
Nestle submitted the highest offer and Merck was likely to select a winner during the first quarter, but might also choose not to sell the assets after all.
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.
MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial.
Since the acquisition fell apart, Allergan has fallen on some hard times.
Will this new buy be enough for Celgene investors?